Related Experiment Videos

Effect of hemodialysis on gallium-67-citrate scanning

Clinical Nuclear Medicine
|September 1, 1980
PubMed

Insights

Gallium-67 citrate scans for detecting inflammation in hemodialysis patients are not affected by the dialysis process. The study found no significant loss of gallium during dialysis, ensuring scan quality remains high.

Area of Science:

  • Nuclear Medicine
  • Nephrology

Background:

  • Gallium-67 citrate scanning is a key diagnostic tool for inflammatory conditions.
  • Its use in hemodialysis patients raises concerns about potential interference from the dialysis procedure.

Purpose of the Study:

  • To investigate whether hemodialysis affects the quality and accuracy of Gallium-67 citrate scans.
  • To quantify any potential loss of Gallium-67 during the dialysis process.

Main Methods:

  • Nine hemodialysis patients were studied, with eight undergoing hollow-fiber dialysis and one undergoing ultrafiltration.
  • Blood and dialysate samples were analyzed during dialysis.
  • Whole-body scans were performed 24 hours post-injection.

Main Results:

  • Blood sampling showed no significant decrease in gallium concentration due to dialysis.
  • While dialysate activity was detected, reliable quantification of gallium loss was not achieved.
  • Ultrafiltration removed approximately 0.5% of the injected gallium dose.
  • Whole-body scans demonstrated good image quality, with total counts unaffected by dialysis.

Conclusions:

  • Hemodialysis does not adversely impact the quality of Gallium-67 citrate scans.
  • The timing of gallium injection relative to dialysis also does not affect scan quality.
  • Gallium-67 citrate scanning remains a reliable diagnostic method for inflammatory processes in hemodialysis patients.

Related Concept Videos